EQRx chairman Alexis Borisy and CEO Melanie Nallichieri

EQRx, CStone un­furl full lung can­cer da­ta for PD-L1 drug in what the part­ners are call­ing a first

As a self-styl­ized drug pric­ing dis­rup­tor, EQRx has high hopes for its lead PD-(L)1 to of­fer proof of con­cept for the en­tire busi­ness mod­el. Af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.